Medtronic backs Israel's Pi-Cardia with up to $80M, eyes $210M buyout
What's the deal? MedtronicDealroom has a profile for this one. Try Dealroom → will invest up to $80 million in Pi-Cardia, an Israeli developer of leaflet modification technology for structural heart disease. The late-stage round, announced September 1, was led by Medtronic alongside Sofinnova Partners, Sprig EquityDealroom has a profile for this one. Try Dealroom →, and Jacques Séguin.
What does Pi-Cardia do? Founded by Erez Golan and Eyal Kolka, the Rehovot-based company makes ShortCut, the first FDA-cleared leaflet modification device. It is designed to enable valve-in-valve transcatheter aortic valve replacement (TAVR) in patients at risk of coronary obstruction.
In FDA-reviewed studies, ShortCut showed successful leaflet splitting in all pivotal trial patients, with a favourable safety profile.
What's the endgame? The deal is more than an investment. Medtronic is set to become ShortCut's exclusive global distributor in 2027, using its structural heart organisation to expand access across the US, Europe, Japan, and other markets.
The agreement also gives Medtronic an option to acquire Pi-Cardia once it hits predefined milestones, at an estimated upfront price of up to $210 million, plus potential earn-out payments.
Why now? "As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of Medtronic's Structural Heart business. Chief executive officer Erez Golan said Medtronic is "the right partner" given its global reach.
What could go wrong? The investment, distribution deal, and acquisition option are all subject to regulatory approval and customary closing conditions. The buyout hinges on Pi-Cardia meeting undisclosed milestones.
The signal: The round sits in the 93rd percentile by size among all-time late-stage venture deals in Israeli health, based on a sample of 132. It reflects a growing pattern of medtech incumbents securing early options on niche innovations — Medtronic committed $35 million to Orchestra BioMed weeks earlier — rather than waiting to compete for them later.
Read more: stocktitan.net
Image credit: Ruhrfisch
